By Myles Starr
A new report in the Journal of Managed Care & Specialty Pharmacy outlines how the emergence of artificial intelligence, growth of therapeutics such as cell and gene therapies (CGTs), and significant regulatory changes are likely to disrupt the managed care industry. Pharmacies will need to advocate for public policies and new payment models that effectively manage the costs, risks and opportunities associated with these changes (2025;31[2-a suppl]:S2-S10).
“Furthermore,